Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT07015801
NA
CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency
Sponsor: University of Calgary
View on ClinicalTrials.gov
Summary
Treatment of CMV in a patient with profound combined immunodeficiency, who has viremia and pneumonia, using CMV-specific donor-derived T lymphocytes (CMV-VST).
Official title: Open-label Individual Patient Study of Cytomegalovirus (CMV)-Specific Donor-derived T Lymphocytes (DTL) for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency
Key Details
Gender
FEMALE
Age Range
0 Years - 20 Years
Study Type
INTERVENTIONAL
Enrollment
1
Start Date
2025-04-15
Completion Date
2040-04
Last Updated
2025-06-11
Healthy Volunteers
No
Interventions
BIOLOGICAL
CMV-VST
30-40 x 10\^3 viable CD3+ cells/kg
Locations (1)
Alberta Children's Hospital
Calgary, Alberta, Canada